质子束治疗肝细胞癌:日本多中心前瞻性登记研究
日本于2016年5月启动多中心前瞻性登记研究,评估质子束治疗(PBT)肝细胞癌(HCC)的疗效与安全性。576例初治PBT患者中位随访39个月,中位总生存48.8个月,3年局部控制率90%,≥3级晚期不良事件27例(4.7%)。
要点
- 576例初治HCC患者接受PBT,中位总生存48.8个月,3年局部控制率90%。
- 肿瘤<5cm较5-10cm及≥10cm、Child-Pugh A/B较C、肿瘤距胃肠道<1cm较1-2cm及>2cm的1-4年OS显著更高(P<.001或P<.008)。
- ≥3级晚期不良事件27例(4.7%),最常见为肝衰竭(n=7)和皮炎(n=7)。
核心结论
- 多中心前瞻性登记数据显示,PBT治疗HCC疗效良好(3年局部控制率90%),严重晚期不良事件风险低。
研究设计与样本
- 日本多中心前瞻性登记研究,2016年5月至2018年6月注册接受PBT的HCC患者。
- 755例注册患者中,576例初治PBT且无重复癌者纳入评估。
主要发现
- 末次随访时322例存活、254例死亡;存活者中位随访39个月(0-58个月)。
- 576例中位OS为48.8个月(95%CI 42.0-55.6个月),1、2、3、4年OS率分别为83.8%(80.5%-86.6%)、68.5%(64.5%-72.2%)、58.2%(53.9%-62.2%)、50.1%(44.9%-55.0%)。
- 332例出现复发,其中45例局部复发;中位PFS为14.7个月(95%CI 12.4-17.0个月),1、2、3、4年PFS率分别为55.2%(51.0%-59.2%)、37.5%(33.5%-41.5%)、30.2%(26.3%-34.2%)、22.8%(18.5%-27.4%)。
- 1-4年OS率在肿瘤大小<5cm vs 5-10cm(P<.001)、<5cm vs ≥10cm(P<.001)、Child-Pugh评分A/B vs C(P<.001)、肿瘤距胃肠道<1cm vs 1-2cm(P<.008)、<1cm vs >2cm(P<.001)之间均显著更高。
- 末次随访时27例(4.7%)发生≥3级晚期不良事件,最常见为肝衰竭(n=7)和皮炎(n=7)。
关键数值与推荐
- 3年局部控制率为90%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A prospective multicenter registry study was started May 2016 in Japan to evaluate the efficacy and safety of proton beam therapy (PBT) for hepatocellular carcinoma (HCC). METHODS AND MATERIALS: Patients who received PBT for HCC from May 2016 to June 2018 were registered in the database of the Particle Beam Therapy Committee and Subcommittee of the Japanese Society for Radiation Oncology. Overall survival (OS), progression-free survival (PFS), and local recurrence were evaluated. RESULTS: Of the 755 registered patients, 576 with initial PBT and no duplicate cancer were evaluated. At final follow-up, 322 patients were alive and 254 had died. The median follow-up period for survivors was 39 months (0-58 months). The median OS time of the 576 patients was 48.8 months (95% CI, 42.0-55.6 months) and the 1-, 2-, 3-, and 4-year OS rates were 83.8% (95% CI, 80.5%-86.6%), 68.5% (64.5%-72.2%), 58.2% (53.9%-62.2%), and 50.1% (44.9%-55.0%), respectively. Recurrence was observed in 332 patients, including local recurrence in 45 patients. The median PFS time was 14.7 months (95% CI, 12.4-17.0 months) and the 1-, 2-, 3-, and 4-year PFS rates were 55.2% (95% CI, 51.0%-59.2%), 37.5% (33.5%-41.5%), 30.2% (26.3%-34.2%), and 22.8% (18.5%-27.4%), respectively. The 1-, 2-, 3-, and 4-year OS rates were significantly higher for tumor size <5 versus 5 to 10 cm (P < .001) and <5 versus ≥10 cm (P < .001); Child-Pugh score A/B versus C (P < .001); and distance of the tumor from the gastrointestinal tract <1 versus 1 to 2 cm (P < .008) and <1 versus >2 cm (P < .001). At final follow-up, 27 patients (4.7%) had late adverse events of grade 3 or higher, with liver failure (n = 7), and dermatitis (n = 7) being most common. CONCLUSIONS: This multicenter prospective data registry indicated that PBT for HCC gives good therapeutic effects (3-year local control rate of 90%) with a low risk of severe late adverse events.
引用
- Mizumoto M, Ogino H, Okumura T, et al. Proton Beam Therapy for Hepatocellular Carcinoma: Multicenter Prospective Registry Study in Japan. Int J Radiat Oncol Biol Phys. 2023. PMID: 37778422. doi:10.1016/j.ijrobp.2023.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。